Citius Oncology (CTOR) Income Statement: Revenue & Earnings

Citius Oncology Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Citius Oncology, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 2025	Sep 2024	Sep 2023	Sep 2022
Revenue & Gross Profit
Revenue	0.00	0.00	0.00	0.00
Cost of Revenue	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00
Operating Expenses
Research & Development	6.42	4.93	4.24	6.86
Selling, General & Administrative	17.10	8.15	7.88	2.86
Operating Expenses	23.52	20.57	12.12	9.71
Operating Income	-23.52	-20.57	-12.12	-9.71
Other Income/Expense
Interest Income	0.04	0.00	0.00	0.00
Interest Expense	0.22	0.00	0.00	0.00
Other Income/Expense	-0.18	0.00	0.00	0.00
Income
Income Before Tax	-23.70	-20.57	-12.12	-9.71
Income Tax Expense	1.06	0.58	0.58	1.15
Net Income	-24.76	-21.15	-12.70	-10.87
Net Income - Continuous Operations	-24.76	-21.15	-12.70	-5.43
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00
EBITDA	-23.49	-20.57	-12.12	-4.86
EBIT	-23.49	-20.57	-12.12	-9.71
Depreciation & Amortization	0.00	0.00	0.00	0.00
Earnings Per Share
Basic EPS	-	-	-	-
Diluted EPS	-	-	-	-
Basic Shares Outstanding	73.27	68.05	71.24	33.75
Diluted Shares Outstanding	73.27	68.05	71.24	33.75